Talk:Agomelatine
From Wikipedia, the free encyclopedia
 |
Agomelatine is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome. |
| Stub | This article has been rated as stub-Class on the quality scale. |
|
|
|
On 27 July 2006 the Committe for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. The CHMP had no special concerns about the side effects. See <http://www.emea.eu.int/pdfs/human/opinion/267703062en.pdf>.
